Healthcare
Live Price
Offline$0.0004
+0.00% today
1Y Change
+33.33%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ViaDerma, Inc. (VDRM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 33.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +11.1%, EPS growth of -100.0%, a dividend yield of 0.0%. What stands out right now is revenue +11.1%, EPS -100.0%, free cash flow +111.7% with operating margin 30.9% and ROIC 41.5%. Valuation already assumes a fairly strong business story at P/E 115.0 and price/sales 0.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VDRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VDRM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VDRM Max Drawdown
-94.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VDRM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.4K
-9.4% YoY
FY Net Income
-$599.3K
-38.8% YoY
Free Cash Flow
-$15.1K
-72.4% YoY
Revenue Growth
+11.1%
EPS Growth
-100.0%
Gross Margin
100.0%
Net Margin
0.7%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 600K | 541K | 514K | 11K | 10K |
| Gross Profit | 600K | 540K | 511K | 11K | 10K |
| Operating Income | 185K | 245K | 328K | -71K | -338K |
| EBITDA | 81K | 690K | -883K | -283K | -338K |
| Net Income | 4K | 591K | -994K | -432K | -599K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10K | 10K | 12K | 10K | 10K |
| Total Assets | 1M | 714K | 275K | 123K | 69K |
| Total Liabilities | 1M | 3M | 3M | 2M | 3M |
| Shareholder Equity | 123K | -2M | -2M | -2M | -3M |
| Total Debt | 323K | 415K | 415K | 589K | 770K |
| Net Debt | 313K | 405K | 404K | 578K | 760K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15K
-72.4% YoY
Capital Expenditures
0
Free Cash Flow
15K
-72.4% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
30.9%
Net Margin
0.7%
ROE
-0.5%
Debt / Equity
2.62x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.